10599-17-4

Basic information

• Product Name: 1-(3-chloropropyl)-4-phenylpiperazine
• Synonyms: Piperazine, 1-(3-chloropropyl)-4-phenyl-; Piperazine, 1-(3-chloropropyl)-4-phenyl-,
• CAS NO: 10599-17-4
• Molecular Formula: C₁₃H₁₉ClN₂
• Molecular Weight: 238.7564
• Mol File: 10599-17-4.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 354.5°C at 760 mmHg
• Flash Point: 168.2°C
• Density: 1.094g/cm³
• Vapor Pressure: 3.32E-05mmHg at 25°C
• Refractive Index: 1.543
• CAS DataBase Reference: 1-(3-chloropropyl)-4-phenylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-chloropropyl)-4-phenylpiperazine(10599-17-4)
• EPA Substance Registry System: 1-(3-chloropropyl)-4-phenylpiperazine(10599-17-4)

Safety Data

• Hazardous Substances Data: 10599-17-4(Hazardous Substances Data)

Upstream product

• 92-54-6 4-phenyl-1-piperazine 
• 109-70-6 1.3-chlorobromopropane 
• 4004-95-9 1-phenylpiperazine hydrochloride 
• 62-53-3 aniline 
• 67514-07-2 1-phenyl-4-(3-hydroxypropyl)piperazine 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 164071-35-6 3,7-Dimethyl-2-[3-(4-phenyl-piperazin-1-yl)-propyl]-5-piperidin-1-yl-2,3-dihydro-pyrido[3,4-d]pyridazine-1,4-dione 
• 164357-33-9 2H-2,3,7,9-tetramethyl-4-<3-(4-phenyl-1-piperazinyl)propyl>-2,4-dihydropyrazolo<4,3-c>pyrido<3,2-e>-1,2-thiazine-5,5-dioxide 
• 80428-34-8 1-[3-(4-acetamido-2-methoxyphenoxy)-n-propyl]-4-phenyl-piperazine 
• 56079-60-8 3-[3-(4-phenyl-1-piperazinyl)propyl]-5,5-diphenyl-hydantoin maleate 
• 134858-69-8 (4-Chloro-phenyl)-(5-methoxy-3-methyl-2-{4-[3-(4-phenyl-piperazin-1-yl)-propoxy]-phenyl}-indol-1-yl)-methanone; hydrochloride 
• 134858-70-1 1-(4-chlorobenzoyl)-6-methoxy-2-<4-<3-N¹-(N⁴-phenylpiperazinyl)propoxy>phenyl>indole dihydrochloride 
• 134858-60-9 4-[3-(4-Phenyl-piperazin-1-yl)-propylsulfanyl]-phenylamine 
• 103074-79-9 2-{3-[3-(4-Phenyl-piperazin-1-yl)-propoxy]-phenyl}-thiazolidine-3-carbothioic acid methylamide 
• 103074-81-3 2-{4-[3-(4-Phenyl-piperazin-1-yl)-propoxy]-phenyl}-thiazolidine-3-carbothioic acid methylamide 
• 119321-65-2 1-<6-(1,2,3,4-Tetrahydroquinoloxy)>-3-1-(N⁴-phenylpiperazinyl)>propane 
• 78702-83-7 N-{3-[3-(4-Phenyl-piperazin-1-yl)-propoxy]-phenyl}-formamide 

Relevant articles and documents

Synthesis, 5-HT(1A) and 5-HT(2A) receptor affinity of new 1-phenylpiperazinylpropyl derivatives of purine-2,6- and pyrrolidine-2,5-diones

Two series of 1-phenylpiperazinylpropyl derivatives 10, 11, 16, 17 and 19-24, structurally related to previously described 5-HT(1A) or 5-HT(2A) ligands 4 and 1, respectively, were synthesized and their binding properties were determined. Structural modifi

Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands

Two series of hybrid analogues were designed, synthesized, and evaluated as a novel class of selective ligands for the dopamine D3 receptor. Binding affinities of target compounds were determined (using the method of radioligand binding assay). Compared to comparator agent BP897, compounds 2a and 2c were found to demonstrate a considerable binding affinity and selectivity for D3 receptor, and especially compound 2h was similarly potent and more selective D3R ligand than BP897, a positive reference. Thus, they may provide valuable information for the discovery and development of highly potent dopamine D3 receptor ligands with outstanding selectivity.

Design, synthesis, and biological evaluation of arylpiperazine-benzylpiperidines with dual serotonin and norepinephrine reuptake inhibitory activities

The limitations of established serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake inhibitors necessitate the development of safer and more effective therapeutic agents. Based on the structures of 4-benzylpiperidine carboxamides and trazodone, arylpiperazine-benzylpiperidines with chemical scaffolds different from those of marketed drugs were designed, synthesized, and evaluated for their neurotransmitter reuptake inhibitory activities. The majority of the synthesized compounds showed greater NE than 5-HT reuptake inhibition. The activities were even greater than those of the standard drug, venlafaxine hydrochloride were. The derivatives with a three-carbon linker showed better activities than the derivatives with a two-carbon linker. Among the newly synthesized compounds, 2d exhibited the strongest reuptake inhibition of the neurotransmitters (IC50 = 0.38 μM for NE and 1.18 μM for 5-HT). The biological activity data demonstrate that arylpiperazine-benzylpiperidines have the potential to be developed as a new class of therapeutic agents to treat neuropsychiatric and neurodegenerative disorders.